Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Delaware for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Delaware only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Delaware (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Jamal Misleh (NPI 1174665822)

Field	Value
Entity Type	Individual
Organization	Jamal Misleh
Address	4701 Ogletown Stanton Rd
City	Newark
State	DE
ZIP	19713
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	February 12, 2007

Payer Source	Total Paid
Medicare	$6.8M
Medicaid	$0

Key Findings

This profile is effectively single‑payer: Total Medicare revenue is $6.8M and there is no Medicaid billing on file. The provider’s entire reported revenue base for public payers is concentrated in Medicare, so payer-mix strategies and competitive comparisons should be evaluated primarily against Medicare peers.

Revenue is highly concentrated in a small set of biologic/immunotherapy drugs: J9271 generates $2.8M (42.5%), J9144 generates $1.3M (19.6%), and J9312 generates $406.4K (6.1%); the top 3 Medicare codes by revenue account for 68.1% of this provider's total Medicare revenue. This concentration indicates most Medicare dollars are driven by a few high-cost oncology agents rather than a broad mix of low-cost E/M visits.

The code mix and descriptions indicate an infusion‑centric hematology/oncology practice that administers high-cost monoclonal antibodies and checkpoint inhibitors on an outpatient basis. High-revenue drug codes such as J9271 (pembrolizumab) and J9144 (daratumumab), together with chemotherapy administration codes like 96413 and add-on/continuation codes (96415, 96417), point to sustained infusion throughput and multi-agent sessions rather than a visit-heavy primary care model.

Operational patterns are consistent with an office-based infusion suite and care continuity into the community: G0498 appears with $28.9K revenue and ranks #7 of 896 providers nationally (99th percentile; extreme outlier), and multiple add-on infusion codes (96415, 96417, 96375) are flagged as extreme outliers or notably above typical national volume. These items suggest frequent, extended infusion encounters and possible coordination of pump-based or home-continuation infusions.

The provider is a national outlier on several high-cost medications and administration codes, indicating dominant volume in specific therapy lines: J9271 ranks #8 of 1841 providers nationally (100th percentile; extreme outlier) and J9144 ranks #7 of 615 providers nationally (99th percentile; extreme outlier). By contrast, some agents such as J9312 (rank #38 of 317, 88th percentile) and J9299 (rank #264 of 505, 48th percentile) show more typical participation, so dominance is concentrated in a subset of products.

Supportive care and adjunctive therapies are also a meaningful part of the mix: J1568 accounts for $383.4K (5.7%), J9299 accounts for $343.2K (5.1%), J0897 accounts for $290.5K (4.3%), and Q5122 accounts for $154.4K (2.3%). The presence of immune globulin, growth-factor agents, and bone-modifying therapy alongside checkpoint inhibitors and monoclonals signals a comprehensive oncology care approach that includes toxicity management and survivorship support.

Several administration and procedural codes are extreme outliers nationally, reinforcing the picture of high infusion throughput and complex sessions: 96413 ranks #17 of 7514 providers nationally (100th percentile; extreme outlier), 96415 ranks in the 99th percentile, 96375 ranks in the 99th percentile, and J1454 ranks #2 of 422 providers nationally (100th percentile; extreme outlier). These statistical flags suggest this provider treats an unusually large Medicare infusion volume compared with national peers and may operate at scale for particular therapy regimens.

The provider has long tenure in Medicare billing with an NPI enumerated 2007-02-12 (~19 years ago), which may contribute to an established referral network and patient base that supports sustained, high-volume administration of specialty oncology drugs. Given the absence of Medicaid activity and the concentration in Medicare-paid biologics, competitive and utilization benchmarking should focus on national Medicare peers for infusion services and high-cost oncology agents.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

65 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	66,000	$40	$2.8M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	34,380	$40	$1.3M
J9312	Injection, rituximab, 10 mg	6,350	$60	$406.4K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	11,980	$30	$383.4K
J9299	Injection, nivolumab, 1 mg	14,300	$20	$343.2K
J0897	Injection, denosumab, 1 mg	16,140	$20	$290.5K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	1,610	$100	$154.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,470	$100	$153.3K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	5,410	$30	$135.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,040	$100	$100K

Showing 1–10 of 65

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 65 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Delaware Distribution

Jamal Misleh — 17 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Delaware

Full comparison — all codes billed, vs. state median

65 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	10	17,600	$40	$992.4K
J9144	1	10	9,360	$40	$420.8K
J9299	2	10	14,300	$20	$329.6K
J9312	1	10	5,250	$60	$314K
J1568	1	10	2,660	$30	$146.7K
J0897	6	60	3,360	$20	$132.9K
J1449	1	10	3,960	$20	$97.4K
Q5122	1	10	400	$100	$61.8K
J0881	1	10	25,410	$1	$57.7K
J2506	1	10	590	$90	$51.1K

Showing 1–10 of 65

Related Providers

Other providers that share a Tax Identification Number (TIN) with Jamal Misleh, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Medical Oncology Hematology Consultants PA	DE	Hematology & Oncology Physician	$0	$7.7M
Dhaval Shah	DE	Hematology & Oncology Physician	$2.5M	$0
Gregory Masters	DE	Medical Oncology Physician	$2.3M	$0
Evan Lapinsky	DE	Hematology & Oncology Physician	$1.7M	$0
Lydia Clements	DE	Medical Oncology Physician	$1.3M	$0
Sujung Park	DE	Hematology & Oncology Physician	$1.2M	$0
Amy Mcghee Jez	DE	Hematology & Oncology Physician	$1.1M	$0
Andrew Himelstein	DE	Hematology & Oncology Physician	$1.1M	$0
Roberto Ferro Valdes	SD	Hematology & Oncology Physician	$1.1M	$0
Martha Hosford Skapof	DE	Hematology & Oncology Physician	$748.2K	$0

Nearby Providers

Other providers in the same ZIP code as Jamal Misleh, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Associated Retinal Consultants LLC	DE	Ophthalmology Physician	$0	$25.2M
Columbus Medical Services, LLC	DE	Case Management Agency	$0	$18.7M
Christiana Care Health Services Inc	DE	Hospitalist Physician	$0	$13.6M
Caritas Home Health Services, Inc	DE	Home Health Agency	$0	$11.2M
Delaware Center For Maternal Fetal Medicine Of Christiana Care	DE	Maternal & Fetal Medicine Physician	$0	$9.8M
Christiana Care Health Services Inc	DE	Neonatal-Perinatal Medicine Physician	$0	$8.9M
Christiana Care Quality Partners	DE	Urgent Care Clinic/Center	$0	$7M
Mid-atlantic Behavioral Health, LLC	DE	Intellectual & Developmental Disabilities Psychologist	$0	$6.5M
First State Orthopaedics, PA	DE	Orthopaedic Surgery Physician	$0	$6M
Autism Delaware	DE	Intellectual & Developmental Disabilities Psychologist	$0	$5.8M

Jamal Misleh — Billing Profile & Reimbursement Data

Sign up for Jamal Misleh — Billing Profile & Reimbursement Data policy alerts

Jamal Misleh — Billing Profile & Reimbursement Data

Sign up for Jamal Misleh — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References